Biomarker Screening for Lung Cancer
(NYULCBC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to enhance lung cancer screening by studying biomarkers, substances in the body that can indicate cancer presence. The goal is to detect lung cancer early and aid in planning effective treatments. Individuals who have smoked the equivalent of a pack a day for 20 years or more, or who have been referred for lung nodule evaluation, might be suitable for this study. As a Phase 2 trial, this research measures the effectiveness of the screening method in an initial, smaller group, offering participants a chance to contribute to advancements in early lung cancer detection.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What prior data suggests that this screening is safe for participants?
Research has shown that using biomarkers for lung cancer screening is generally safe. Biomarkers are substances in the body that can indicate cancer. Studies have found that tests for these biomarkers, such as taking a small tissue sample from the lungs, are usually well-tolerated by patients.
No major reports of serious side effects from these tests have emerged. Most patients undergo the tests without significant problems. The purpose of using biomarkers is to detect lung cancer early when it's easier to treat, aiding doctors in planning more effective treatments. While any medical test carries some risk, evidence suggests that biomarker screening for lung cancer is a safe option for most people.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it focuses on identifying biomarkers and improving screening methods for lung cancer. Unlike traditional screening techniques, which often rely on imaging and may detect cancer at a later stage, this approach aims to catch the disease earlier by identifying specific biological markers in the body. Early detection can significantly improve treatment outcomes, making this a promising area of research. By refining how we screen for lung cancer, we hope to increase early diagnosis rates and improve survival chances for patients.
What evidence suggests that this screening is effective for lung cancer?
Research has shown that biomarker screening is a promising method for early lung cancer detection. One study found this method to be 93% accurate in identifying individuals without cancer. However, it correctly identified cancer in only 40% of cases, which is less than ideal. Despite this, another report suggests that thorough biomarker testing can help doctors select more effective treatments. Overall, early detection of lung cancer with these methods could significantly reduce mortality from the disease.16789
Who Is on the Research Team?
James J. Tsay, MD, MSc
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Biomarker Identification
Participants undergo tests to identify and validate biomarkers for early detection of lung cancer
Follow-up
Participants are monitored for preneoplastic cellular changes and lesions
What Are the Treatments Tested in This Trial?
Interventions
- Screening
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
Citations
IASLC Global Survey on Biomarker Testing in Lung Cancer
Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. Our survey is now closed.
New Report: Lung Cancer Advancements Are Saving More ...
The report shows progress in coverage of comprehensive biomarker testing for lung cancer, which can help physicians identify better, more ...
Biomarkers in lung cancer screening: achievements ...
In a clinical validation study including all lung cancer histologies and stages the panel performed well with 93% specificity, but only 40% sensitivity.
Five year mortality in an RCT of a lung cancer biomarker to ...
Following the landmark National Lung Screening Trial (NLST) LDCT screening has been shown to detect cancers earlier and reduce lung cancer mortality by 20–25% [ ...
Biomarker Testing, Treatment, and Outcomes in Patients ...
Background: Little is known about the impact of up-front biomarker testing on long-term outcomes in patients with advanced or metastatic ...
Safety and Sample Adequacy for Comprehensive ...
Safety and sample adequacy for comprehensive biomarker testing of bronchoscopic biopsies: An American Association of Bronchology and Interventional Pulmonology ...
Biomarker Tests
Comprehensive biomarker testing is used among diagnosed lung cancer patients to determine the presence of particular mutations or of a particular protein.
8.
aacrjournals.org
aacrjournals.org/cebp/article/29/12/2411/72168/Biomarkers-for-Lung-Cancer-Screening-andBiomarkers for Lung Cancer Screening and Detection
Biomarkers have tremendous potential to improve early detection of lung cancer by refining lung cancer risk, stratifying positive CT scans, and ...
Assessment of Biomarker Testing for Lung Cancer ...
This exploratory study analyzes the cost-effectiveness of incorporating biomarkers into eligibility assessment for lung screening.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.